JPRN-UMIN000003282已完成1 期
Phase 1-2 Study of Amrubicin plus Nedaplatin for Advanced Non-Small-Cell Lung Cancer - Phase 1-2 Study of Amrubicin plus Nedaplatin for Advanced Non-Small-Cell Lung Cancer
agasaki University Hospital0 个研究点目标入组 35 人开始时间: 2010年3月3日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 35
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- ot applicable 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1.Symptomatic pericardial effusion 2.Symptomatic SVC syndrome required emergency radiation 3.Serious medical complications 4.uncontrolled angina pectoris, myocardial infarction within 3 months, heart failure. 5.Uncontrolled diabetes mellitus, hypertension, infection 6.Pulmonary fibrosis detectable on chest X-ray films 7.Concomitant malignancy 8.Pregnant or milk-feeding female 9.Symptomatic brain metastasis 10.Other clinical difficulties to this study
研究者
相似试验
已完成
2 期
Phase II study of amrubicin for previously treated advanced non-small cell lung cancerRecurrent non-small cell lung cancerJPRN-UMIN000001751Gunma University Hospital35
招募中
1 期
Phase I study of Amrubicin plus CISplatin and concurrent accelerated hyperfractionated thoracic radioTherapy for limited-disease small cell lung cancerJPRN-jRCT1071200033Taniguchi Hirokazu9
已完成
2 期
A phase II study of amrubicin for previously treated small cell lung cancerFor patients with recurrent small cell lung cancerJPRN-UMIN000001752Gunma University Hospital35
已完成
不适用
Phase 2 study of amrubicin in previously treated patients with malignant pleural mesotheliomaMalignant pleural mesotheliomaJPRN-UMIN000006381agasaki University Hospital32
已完成
不适用
Phase II study of amrubicin combined with carboplatin for unresectable invasive thymoma or thymic carcinomaThymoma/Thymic carcinomaJPRN-UMIN000002619Tohoku University Hospital40